The failure of Roche’s frontrunner TIGIT immunotherapy tiragolumab in a second Phase III trial has not only dragged down the Swiss pharma’s prospects, but also the share price of its biotech rivals.
No-one is writing tiragolumab off just yet, but faith in the TIGIT mechanism has been badly dented, and there are...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
